Today, on November 1, Uber will release its report for the third quarter of the current financial year. Wedbush’s analysts expect that this report will demonstrate the company’s solid results.
Today, on November 1, Uber will release its report for the third quarter of the current financial year. Wedbush’s analysts expect that this report will demonstrate the company’s solid results.
On Monday, the FTSE 100 closed at a fresh five-week high. According to Reuters, the rise in the FTSE 100 can be explained by the fact that the fall of the pound sterling raised the income of such dollar companies as AstraZeneca and Unilever.
The Bank of England came up with the decision to start selling assets from the quantitative easing asset portfolio on November 1. The UK central bank postponed the start of the second gilt sale operations as they may coincide with the government’s fiscal statement, as reported by Bloomberg.
On Friday, Exxon Mobil Corp showed a record quarterly profit, driven by rising oil and gas prices. The company's profit margin has almost reached the level of Apple.
On Thursday, last week, Elon Musk finally acquired Twitter. His first act as head of the company was to fire top executives, but along with this he also clarified how he sees the future of the company and the social network and what he plans to achieve.
Chevron Corp posted its second-highest quarterly profit ever, beating analysts' estimates.
The European Central Bank (ECB) hiked interest rates by 75 basis points on Thursday, October 27. A further monetary tightening is foreseen, along with a subsequent slowdown in economic growth.
Mastercard Inc. on Thursday dismissed fears of slower consumer spending growth after a lower-than-expected revenue growth forecast for the last three months of the year overshadowed an upbeat quarter for the U.S. payment system.
According to a Reuters poll, on Tuesday, the Reserve Bank of Australia (RBA) will raise interest rates again by a modest 25 basis points, despite the record level of inflation registered for the first time in thirty years.
Merck & Co. reported better-than-expected Q3 sales and earnings Thursday. Those results came on the back of a jump in demand for Keytruda cancer immunotherapy and the human papillomavirus vaccine Gardasil.